Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks .

What is Aeterna Zentaris' stock price target for 2024?

1 analysts have issued twelve-month target prices for Aeterna Zentaris' stock. Their AEZS share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 621.2% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts .

How have AEZS shares performed in 2023?

Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS stock has decreased by 34.6% and is now trading at $2.08. View the best growth stocks for 2023 here .

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AEZS earnings forecast .

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.24. Aeterna Zentaris had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 340.56%.

When did Aeterna Zentaris' stock split?

Aeterna Zentaris's stock reverse split on the morning of Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN) , Pennsylvania Real Estate Investment Trust (PEI) , CBL & Associates Properties (CBL) , Gran Tierra Energy (GTE) , CNBX Pharmaceuticals (CNBX) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Novan (NOVN) and Washington Prime Group (WPG) .

Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aeterna Zentaris Stock Price, News & Analysis (NASDAQ:AEZS)

$2.08

+0.10 (+5.05%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.96
▼
$2.08
50-Day Range: $1.42
▼
$2.50
52-Week Range: $1.36
▼
$4.00

Volume: 5,869 shs
Average Volume: 11,036 shs
Market Capitalization: $10.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Aeterna Zentaris MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 621.2% Upside
$15.00 Price Target
Short Interest: Bearish
0.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.22) to ($3.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

652nd out of 957 stocks

Pharmaceutical Preparations Industry

311th out of 443 stocks

3.5

Analyst's Opinion

Consensus Rating
Aeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Aeterna Zentaris has a forecasted upside of 621.2% from its current price of $2.08.
Amount of Analyst Coverage
Aeterna Zentaris has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.98% of the float of Aeterna Zentaris has been sold short.
Short Interest Ratio / Days to Cover
Aeterna Zentaris has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Aeterna Zentaris has recently increased by 1.50%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Aeterna Zentaris does not currently pay a dividend.
Dividend Growth
Aeterna Zentaris does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AEZS.

3.9

News and Social Media Coverage

News Sentiment
Aeterna Zentaris has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for AEZS on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Aeterna Zentaris to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.10% of the stock of Aeterna Zentaris is held by insiders.
Percentage Held by Institutions
Only 0.57% of the stock of Aeterna Zentaris is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aeterna Zentaris are expected to decrease in the coming year, from ($3.22) to ($3.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aeterna Zentaris is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aeterna Zentaris is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aeterna Zentaris has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aeterna Zentaris Stock (NASDAQ:AEZS)

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

AEZS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AEZS Stock News Headlines

November 30, 2023 | americanbankingnews.com

Aeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at StockNews.com

November 14, 2023 | morningstar.com

AEterna Zentaris Inc AEZS

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 9, 2023 | msn.com

Aeterna Zentaris GAAP EPS of -$0.85

November 9, 2023 | finance.yahoo.com

Aeterna Zentaris Reports Third Quarter 2023 Financial Results

November 6, 2023 | theglobeandmail.com

AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)

October 30, 2023 | theglobeandmail.com

AEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)

October 11, 2023 | finance.yahoo.com

Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

September 12, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Monday (AEZS)

September 5, 2023 | finance.yahoo.com

Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 15, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)

August 10, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)

August 9, 2023 | finance.yahoo.com

Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates

July 13, 2023 | finance.yahoo.com

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

June 15, 2023 | finanznachrichten.de

Aeterna Zentaris Inc: Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

May 26, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Friday (AEZS)

May 17, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Tuesday (AEZS)

May 15, 2023 | finance.yahoo.com

Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders

May 12, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Aeterna Zentaris (AEZS)

May 10, 2023 | finanznachrichten.de

Aeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2023 Financial Results

May 9, 2023 | finance.yahoo.com

Aeterna Zentaris Reports First Quarter 2023 Financial Results

April 27, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Wednesday (AEZS)

April 6, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc up on Thursday (AEZS)

April 6, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc up on Wednesday (AEZS)

April 6, 2023 | finance.yahoo.com

Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug

April 5, 2023 | finanznachrichten.de

Aeterna Zentaris Inc: Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

See More Headlines

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AEZS
CUSIP: N/A
CIK: 1113423
Web: www.zentaris.com
Phone: (418) 652-8525
Fax: 418-948-9191
Employees: 11
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +621.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,730,000.00
Net Margins: -340.56%
Pretax Margin: -340.56%
Return on Equity: -49.10%
Return on Assets: -30.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.91
Quick Ratio: 9.89

Sales & Book Value

Annual Sales: $5.64 million
Price / Sales: 1.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.41 per share
Price / Book: 0.38

Miscellaneous

Outstanding Shares: 4,860,000
Free Float: 4,851,000
Market Cap: $10.11 million
Optionable: Optionable
Beta: 1.63

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Klaus Paulini Ph.D.
President, CEO & Executive Director
Mr. Giuliano La Fratta
Senior VP of Finance & CFO
Dr. Michael Teifel Ph.D.
Senior VP of Non-Clinical Development & Chief Scientific Officer
Dr. Nicola Ammer M.D.
Chief Medical Officer & Senior VP of Clinical Development
Dr. Matthias Gerlach
Senior Vice President Manufacturing & Supply Chain

Key Competitors

View All Competitors

AEZS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings or view top-rated stocks.
What is Aeterna Zentaris' stock price target for 2024?: 1 analysts have issued twelve-month target prices for Aeterna Zentaris' stock. Their AEZS share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 621.2% from the stock's current price.
View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts.
How have AEZS shares performed in 2023?: Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS stock has decreased by 34.6% and is now trading at $2.08.
View the best growth stocks for 2023 here.
When is Aeterna Zentaris' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AEZS earnings forecast.
How were Aeterna Zentaris' earnings last quarter?: Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.24. Aeterna Zentaris had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 340.56%.

When did Aeterna Zentaris' stock split?: Aeterna Zentaris's stock reverse split on the morning of Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Aeterna Zentaris own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).
Who are Aeterna Zentaris' major shareholders?: Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Aeterna Zentaris?: Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AEZS) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial